Agila receives USFDA approval for Zoledronic Acid injection

Agila Specialties Pvt Ltd, a wholly owned subsidiary of Strides Arcolab Limited, on Wednesday said it has received Abbreviated New Drug Application (ANDA) approval for Zoledronic Acid Injection 4mg/5 mg, packaged in single dose vials.

Zoledronic Acid is used to treat high blood calcium levels (hypercalcemia) that may occur with cancer. It is also used with cancer chemotherapy to treat bone problems that may occur with multiple myeloma and other types of cancer such as breast, lung that have spread to bones.  

According to IMS data, the US market for Zoledronic Acid 5ML is approximately $520 million. The company expects to launch the product shortly.   

In morning trade on BSE, the shares of Strides Arcolab were trading at Rs 900.05, up 2.53%.